Colonic Diseases, Functional: Clinical Trials

39 trials for Colonic Diseases, Functional, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

30 completed, 3 recruiting, 3 terminated, 1 not yet recruiting. 39 Phase 1, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 139Completed 30, Recruiting 3, Terminated 3, Not yet recruiting 1, Unknown 1, Withdrawn 1
Phase 210Completed 9, Recruiting 1

Follow Colonic Diseases, Functional: new trials by email Literature Review of Colonic Diseases, Functional trials Research Report on Colonic Diseases, Functional

Trials (filtered) newest first · largest first

All 39 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SIMBA in Irritable Bowel Syndrome (IBS)
Rifaximin (drug), fluid biopsy capsule - Irritable Bowel Syndrome (IBS), Microbiome
Phase 1Not yet recruitingUniversity of Calgary1802026-11-012026-10-20
Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome
FMT capsule, Placebo - Irritable Bowel Syndrome (IBS)
Phase 1 / Phase 2RecruitingUniversity of Rijeka702026-03-152026-03-18
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
Trimedat® - Irritable Bowel Syndrome, Gallstone Disease
Phase 1RecruitingValenta Pharm JSC362025-11-062026-02-19
A Study of Varenicline in the Treatment of Visceral Sensation
Varenicline - Irritable Bowel Syndrome
Phase 1CompletedMayo Clinic82025-06-012026-01-06
Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
rTMS combined with Live Probiotic tablet, rTMS combined placebo, shamrTMS combined with Live Probiotic tablet - Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D)
Phase 1RecruitingThe First Affiliated Hospital of Soochow University4002024-12-012025-05-07
Saccharomyces Cerevisiae for Irritable Bowel Syndrome
Saccharomyces cerevisiae - Irritable Bowel Syndrome
Phase 1 / Phase 2CompletedZiauddin University302021-03-012022-12-07
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
Olorinab, Placebo - Irritable Bowel Syndrome
Phase 1TerminatedArena Pharmaceuticals12021-01-292021-05-17
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
TD-1473, Itraconazole - Inflammatory Bowel Disease
Phase 1CompletedTheravance Biopharma362018-06-132021-01-14
Therapeutic Oxygen for Gastrointestinal Atony (TOGA)
100% Oxygen - Ileus, Ogilvie Syndrome
Phase 1CompletedUniversity of Florida172018-01-252019-12-12
Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI
Neostigmine and Glycopyrrolate, Iontophoresis - Spinal Cord Injuries, Constipation
Phase 1CompletedJames J. Peters Veterans Affairs Medical Center62018-01-152021-12-30
The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome
Probiotic capsule - IBS - Irritable Bowel Syndrome, Depression, Anxiety
Phase 1 / Phase 2CompletedPrecisionBiotics Group Ltd.402017-09-202020-06-09
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
GSK3352589, Matching Placebo - Irritable Bowel Syndrome
Phase 1CompletedGlaxoSmithKline682017-05-172019-08-09
A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects
GSK3179106, Matched Placebo - Irritable Bowel Syndrome
Phase 1CompletedGlaxoSmithKline462016-06-012017-01-18
A Study to Evaluate Fecal Microbiota Transplantation Engraftment in IBS
fecal microbiota transplantation, placebo fecal microbiota transplantation, FMT with antibiotic pre-treatment (v1) - Irritable Bowel Syndrome
Phase 1CompletedBeth Israel Deaconess Medical Center802016-05-012019-12-23
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers
GSK3179106, Placebo - Irritable Bowel Syndrome
Phase 1CompletedGlaxoSmithKline162015-11-262017-05-08
Effect of Vitamin D3 Supplementation in Treatment of Irritable Bowel Syndrome
Vitamin D3 (Cholecalciferol), placebo - Irritable Bowel Syndrome
Phase 1CompletedAhvaz Jundishapur University of Medical Sciences902015-02-012015-11-30
A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically
linaclotide - Breast Feeding, Constipation
Phase 1CompletedForest Laboratories72014-07-312020-12-19
The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients
Probiotic Clostridium Butyricum, Laxative Polyethylene Glycol - Irritable Bowel Syndrome
Phase 1CompletedShandong University562014-07-012016-08-31
Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)
Daikenchuto (TU-100), Placebo - Irritable Bowel Syndrome, Digestive System Diseases
Phase 1 / Phase 2CompletedTsumura USA402013-08-012016-06-13
Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome
Kyodophilus multi-strain probiotic capsules, Kyodophilus Matching Placebo Capsules - Irritable Bowel Syndrome, Digestive System Diseases
Phase 1 / Phase 2CompletedThe Canadian College of Naturopathic Medicine1002013-06-012015-03-17

Showing 20 of 39. Sign in to see all of them.

Narrower conditions

Irritable Bowel Syndrome (35)  ·  Constipation (7)  ·  Diarrhea (4)  ·  Abdominal Pain (3)  ·  Digestive System Diseases (3)  ·  Gastrointestinal Diseases (2)  ·  Mucopolysaccharidosis IV (2)  ·  Multiple Endocrine Neoplasia Type 2a (2)  ·  Neurogenic Bowel (2)  ·  Pain (2)  ·  Spasm (2)  ·  Spinal Cord Injuries (2)  ·  Anxiety Disorders (1)  ·  Biliary Dyskinesia (1)

Broader conditions

Colonic Diseases (39)  ·  Intestinal Diseases (38)  ·  Gastrointestinal Diseases (37)  ·  Digestive System Diseases (36)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Signs and Symptoms (10)  ·  Signs and Symptoms, Digestive (9)  ·  Neurologic Manifestations (6)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Genetic Diseases, Inborn (5)  ·  Nervous System Diseases (5)  ·  Pathologic Processes (3)  ·  Skin and Connective Tissue Diseases (3)  ·  Behavior (2)

Interventions

Fecal Microbiota Transplantation (2)  ·  Glucagon-Like Peptide 1 (2)  ·  Glycopyrrolate (2)  ·  Lubiprostone (2)  ·  Probiotics (2)  ·  12,13-dihydro-N-methyl-6,11,13-trioxo-5H-benzo(4,5)cyclohepta(1,2-b)naphthalen-5,12-imine (1)  ·  Acupuncture Therapy (1)  ·  Cholecalciferol (1)  ·  GSK3352589 (1)  ·  GW 876008 (1)  ·  Iontophoresis (1)  ·  Itraconazole (1)  ·  Melatonin (1)  ·  N-((1-(3-(1,2,3-triazol-1-yl)propyl)piperidin-4-yl)methyl)-4-amino-5-chloro-2-methoxybenzamide (1)  ·  Neostigmine (1)

Sponsors

GlaxoSmithKline (5)  ·  Mayo Clinic (3)  ·  James J. Peters Veterans Affairs Medical Center (2)  ·  The Canadian College of Naturopathic Medicine (2)  ·  Uppsala University (2)  ·  Ahvaz Jundishapur University of Medical Sciences (1)  ·  Arena Pharmaceuticals (1)  ·  Avera Pharmaceuticals (1)  ·  Baylor College of Medicine (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Dayton Children's Hospital (1)  ·  Dong-A ST Co., Ltd. (1)  ·  Forest Laboratories (1)  ·  Hadassah Medical Organization (1)  ·  Lexicon Pharmaceuticals (1)

Countries

United States (21)  ·  Canada (5)  ·  Australia (3)  ·  Sweden (3)  ·  China (2)  ·  Croatia (1)  ·  Iran (1)  ·  Ireland (1)  ·  Israel (1)  ·  Pakistan (1)  ·  Russia (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

Dugald Seely, ND (2)  ·  Michael Camilleri, MD (2)  ·  Adrian Miranda, MD (1)  ·  Anthony Lembo, MD (1)  ·  Arena CT.gov Administrator (1)  ·  Brian C. Weiner, MD (1)  ·  Christopher N Andrews, MD MSc (1)  ·  Eileen Murphy, PhD (1)  ·  Ikenna Ogbaa, MD (1)  ·  Joao Siffert, MD (1)  ·  John K. DiBaise, M.D. (1)  ·  Kirsten Tillisch, MD (1)

Results publications

PMID 30277655, PMID 18298441, PMID 18390493, PMID 22517769, PMID 25617726, PMID 28483500, PMID 29177486, PMID 33168839, PMID 33606922, PMID 34854473, PMID 35014601, PMID 35295488, PMID 39131150

NIH funding

R01NR005337 (1), R21AT003400 (1), UL1RR024150 (1)